Insider Selling: Septerna (NASDAQ:SEPN) COO Sells 4,000 Shares of Stock

Septerna, Inc. (NASDAQ:SEPN) COO Elizabeth Bhatt sold 4,000 shares of Septerna stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $28.97, for a total value of $115,880.00. Following the completion of the sale, the chief operating officer directly owned 174,209 shares in the company, valued at $5,046,834.73. This represents a 2.24% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Septerna Trading Up 0.7%

Shares of SEPN stock traded up $0.20 on Friday, hitting $27.28. 293,621 shares of the stock were exchanged, compared to its average volume of 299,895. The firm has a market capitalization of $1.22 billion, a P/E ratio of -18.07 and a beta of 3.85. Septerna, Inc. has a fifty-two week low of $4.66 and a fifty-two week high of $31.37. The business has a 50-day moving average of $26.69 and a 200 day moving average of $21.54.

Institutional Trading of Septerna

Hedge funds have recently made changes to their positions in the business. Group One Trading LLC increased its position in Septerna by 111.8% during the 4th quarter. Group One Trading LLC now owns 944 shares of the company’s stock worth $26,000 after buying an additional 8,955 shares during the period. Global Retirement Partners LLC acquired a new position in shares of Septerna in the fourth quarter valued at about $35,000. Russell Investments Group Ltd. acquired a new position in shares of Septerna in the third quarter valued at about $36,000. Caitong International Asset Management Co. Ltd bought a new position in Septerna during the fourth quarter worth about $53,000. Finally, Mirae Asset Global Investments Co. Ltd. acquired a new stake in Septerna in the 4th quarter worth about $61,000.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. JonesTrading started coverage on shares of Septerna in a report on Tuesday, December 23rd. They issued a “buy” rating and a $43.00 price objective on the stock. Wall Street Zen downgraded shares of Septerna from a “strong-buy” rating to a “buy” rating in a research report on Saturday, January 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a research report on Thursday, January 22nd. Zacks Research downgraded shares of Septerna from a “hold” rating to a “strong sell” rating in a research note on Friday, January 23rd. Finally, HC Wainwright raised their price objective on Septerna from $30.00 to $35.00 and gave the company a “buy” rating in a report on Tuesday, January 20th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $33.83.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.